{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:42:48Z","timestamp":1793965368271,"version":"4.8.0"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myeloid sarcoma (MS) is a distinct entity among myeloid neoplasms defined as a tumour mass of myeloid blasts occurring at an anatomical site other than the bone marrow, in most cases concomitant with acute myeloid leukaemia (AML), rarely without bone marrow involvement. MS may also represent the blast phase of chronic myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS). However, the clinical and molecular heterogeneity of AML, as highlighted by the 2022 World Health Organization (WHO) and International Consensus (ICC) classifications, indirectly define MS more as a set of heterogeneous and proteiform diseases, rather than a homogeneous single entity. Diagnosis is challenging and relies mainly on histopathology, immunohistochemistry, and imaging. Molecular and cytogenetic analysis of MS tissue, particularly in isolated cases, should be performed to refine the diagnosis, and thus assign prognosis guiding treatment decisions. If feasible, systemic therapies used in AML remission induction should be employed, even in isolated MS. Role and type of consolidation therapy are not univocally acknowledged, and systemic therapies, radiotherapy, or allogeneic hematopoietic stem cell transplantation (allo-HSCT) should be considered. In the present review, we discuss recent information on MS, focusing on diagnosis, molecular findings, and treatments also considering targetable mutations by recently approved AML drugs.<\/jats:p>","DOI":"10.1007\/s00277-023-05288-1","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T19:02:14Z","timestamp":1686164534000},"page":"1973-1984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Myeloid sarcoma: more and less than a distinct entity"],"prefix":"10.1007","volume":"102","author":[{"given":"Giuseppe G.","family":"Loscocco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"5288_CR1","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/ijc.28012","volume":"133","author":"M Ohanian","year":"2013","unstructured":"Ohanian M, Faderl S, Ravandi F et al (2013) Is acute myeloid leukemia a liquid tumor? Int J Cancer 133:534\u2013543. https:\/\/doi.org\/10.1002\/ijc.28012","journal-title":"Int J Cancer"},{"key":"5288_CR2","first-page":"364","volume-title":"Observations of surgical anatomy, head and neck","author":"A Burns","year":"1811","unstructured":"Burns A (1811) Observations of surgical anatomy, head and neck. United Kingdom Thomas Royce Co, Edinburgh, pp 364\u2013366"},{"key":"5288_CR3","first-page":"97","volume":"17","author":"A King","year":"1853","unstructured":"King A (1853) A case of chloroma. Mon J Med 17:97","journal-title":"Mon J Med"},{"key":"5288_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/00000441-189308000-00003","volume":"106","author":"G Dock","year":"1893","unstructured":"Dock G (1893) Chloroma and its relation to leukemia. Am J Med Sci 106:152\u2013157","journal-title":"Am J Med Sci"},{"key":"5288_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/1097-0142(196502)18:2<253::AID-CNCR2820180218>3.0.CO;2-#","volume":"18","author":"DEFACP Comings","year":"1965","unstructured":"Comings DEFACP (1965) Myeloblastoma preceding blood and marrow evidence of acute leukemia. Cancer 18:253\u2013258","journal-title":"Cancer"},{"key":"5288_CR6","unstructured":"Rappaport H (1966) Tumors of the hematopoietic system. Atlas of tumor pathology, Sect 3, Fasc 8, Armed Forces Institute of Pathology, Washington D.C"},{"key":"5288_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1182\/blood.v35.3.361.361","volume":"35","author":"PH Wiernik","year":"1970","unstructured":"Wiernik PH, Serpick AA (1970) Granulocytic sarcoma (chloroma). Blood 35:361\u2013369. https:\/\/doi.org\/10.1182\/blood.v35.3.361.361","journal-title":"Blood"},{"key":"5288_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/1097-0142(197307)32:1<253::AID-CNCR2820320137>3.0.CO;2-W","volume":"32","author":"AO Fayemi","year":"1973","unstructured":"Fayemi AO, Gerber MA, Cohen I, Davis S, Rubin AD (1973) Myeloid sarcoma. Review of the literature and report of a case. Cancer 32:253\u2013258","journal-title":"Cancer"},{"key":"5288_CR9","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937\u2013951. https:\/\/doi.org\/10.1182\/blood-2009-03-209262","journal-title":"Blood"},{"key":"5288_CR10","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405","journal-title":"Blood"},{"key":"5288_CR11","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36:1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"5288_CR12","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140:1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"issue":"2","key":"5288_CR13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/sj.leu.2404491","volume":"21","author":"SA Pileri","year":"2007","unstructured":"Pileri SA, Ascani S, Cox MC et al (2007) Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia 21(2):340\u2013350. https:\/\/doi.org\/10.1038\/sj.leu.2404491","journal-title":"Leukemia"},{"key":"5288_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3109\/10428190009065844","volume":"39","author":"S Kasahara","year":"2000","unstructured":"Kasahara S, Tsurumi H, Hara T et al (2000) Idiopathic myelofibrosis developing isolated granulocytic sarcoma with der (1;7)(q10; p10) after splenectomy and finally transforming to acute myelogenous leukemia. Leuk Lymphoma 39:427\u2013433. https:\/\/doi.org\/10.3109\/10428190009065844","journal-title":"Leuk Lymphoma"},{"key":"5288_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10238-020-00616-5","volume":"20","author":"G Coltro","year":"2020","unstructured":"Coltro G, Mannelli F, Vergoni F et al (2020) Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature. Clin Exp Med 20:313\u2013320. https:\/\/doi.org\/10.1007\/s10238-020-00616-5","journal-title":"Clin Exp Med"},{"key":"5288_CR16","first-page":"520","volume":"121","author":"JCPJBJLC Hancock","year":"1997","unstructured":"Hancock JCPJBJLC (1997) Trilineage extramedullary myeloid cell tumor in myelodysplastic syndrome. Arch Pathol Lab Med 121:520\u2013523","journal-title":"Arch Pathol Lab Med"},{"key":"5288_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1532\/IJH97.04040","volume":"80","author":"T Imamura","year":"2004","unstructured":"Imamura T, Matsuo S, Yoshihara T et al (2004) Granulocytic sarcoma presenting with severe adenopathy (cervical lymph nodes, tonsils, and adenoids) in a child with juvenile myelomonocytic leukemia and successful treatment with allogeneic bone marrow transplantation. Int J Hematol 80:186\u2013189. https:\/\/doi.org\/10.1532\/IJH97.04040","journal-title":"Int J Hematol"},{"key":"5288_CR18","first-page":"62","volume":"120","author":"KHGKTWCML Elenitoba-Johnson","year":"1996","unstructured":"Elenitoba-Johnson KHGKTWCML (1996) Extramedullary myeloid cell tumors arising in the setting of chronic myelomonocytic leukemia. A report of two cases. Arch Pathol Lab Med 120:62\u201367","journal-title":"Arch Pathol Lab Med"},{"key":"5288_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.bbmt.2011.05.023","volume":"18","author":"M Solh","year":"2012","unstructured":"Solh M, DeFor TE, Weisdorf DJ, Kaufman DS (2012) Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation: better prognosis than systemic relapse. Biol Blood Marrow Transplant 18:106\u2013112. https:\/\/doi.org\/10.1016\/j.bbmt.2011.05.023","journal-title":"Biol Blood Marrow Transplant"},{"key":"5288_CR20","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/1097-0142(197304)31:4<948::AID-CNCR2820310428>3.0.CO;2-N","volume":"31","author":"PI Liu","year":"1973","unstructured":"Liu PI, Ishimaru T, McGregor DH et al (1973) Autopsy study of granulocytic sarcoma (chloroma) in patients with myelogenous leukemia, hiroshima-nagasaki 1949-1969. Cancer 31:948\u2013955. https:\/\/doi.org\/10.1002\/1097-0142(197304)31:4<948::AID-CNCR2820310428>3.0.CO;2-N","journal-title":"Cancer"},{"key":"5288_CR21","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/sj.leu.2402958","volume":"17","author":"A-M Tsimberidou","year":"2003","unstructured":"Tsimberidou A-M, Kantarjian HM, Estey E et al (2003) Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia 17:1100\u20131103. https:\/\/doi.org\/10.1038\/sj.leu.2402958","journal-title":"Leukemia"},{"key":"5288_CR22","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000253592","volume":"122","author":"T-Y Lan","year":"2009","unstructured":"Lan T-Y, Lin D-T, Tien H-F et al (2009) Prognostic factors of treatment outcomes in patients with granulocytic sarcoma. Acta Haematol 122:238\u2013246. https:\/\/doi.org\/10.1159\/000253592","journal-title":"Acta Haematol"},{"key":"5288_CR23","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.3109\/10428194.2014.963080","volume":"56","author":"M Movassaghian","year":"2015","unstructured":"Movassaghian M, Brunner AM, Blonquist TM et al (2015) Presentation and outcomes among patients with isolated myeloid sarcoma: a surveillance, epidemiology, and end results database analysis. Leuk Lymphoma 56:1698\u20131703. https:\/\/doi.org\/10.3109\/10428194.2014.963080","journal-title":"Leuk Lymphoma"},{"key":"5288_CR24","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1200\/JCO.2016.67.5892","volume":"34","author":"C Ganzel","year":"2016","unstructured":"Ganzel C, Manola J, Douer D et al (2016) Extramedullary disease in adult acute myeloid leukemia is common but lacks independent significance: analysis of patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. J Clin Oncol 34:3544\u20133553. https:\/\/doi.org\/10.1200\/JCO.2016.67.5892","journal-title":"J Clin Oncol"},{"key":"5288_CR25","doi-asserted-by":"publisher","first-page":"e592","DOI":"10.1038\/bcj.2017.79","volume":"7","author":"G Goyal","year":"2017","unstructured":"Goyal G, Bartley AC, Patnaik MM et al (2017) Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set. Blood Cancer J 7:e592\u2013e592. https:\/\/doi.org\/10.1038\/bcj.2017.79","journal-title":"Blood Cancer J"},{"key":"5288_CR26","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/sj.bmt.1704223","volume":"32","author":"K-H Lee","year":"2003","unstructured":"Lee K-H, Lee J-H, Choi S-J et al (2003) Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course. Bone Marrow Transplant 32:835\u2013842. https:\/\/doi.org\/10.1038\/sj.bmt.1704223","journal-title":"Bone Marrow Transplant"},{"key":"5288_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/sj.bmt.1702488","volume":"26","author":"K-H Lee","year":"2000","unstructured":"Lee K-H, Lee J-H, Kim S et al (2000) High frequency of extramedullary relapse of acute leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 26:147\u2013152. https:\/\/doi.org\/10.1038\/sj.bmt.1702488","journal-title":"Bone Marrow Transplant"},{"key":"5288_CR28","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.leukres.2013.08.017","volume":"37","author":"H Shimizu","year":"2013","unstructured":"Shimizu H, Saitoh T, Hatsumi N et al (2013) Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia. Leuk Res 37:1477\u20131481. https:\/\/doi.org\/10.1016\/j.leukres.2013.08.017","journal-title":"Leuk Res"},{"key":"5288_CR29","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.bbmt.2012.05.010","volume":"18","author":"S Yoshihara","year":"2012","unstructured":"Yoshihara S, Ando T, Ogawa H (2012) Extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: an easily overlooked but significant pattern of relapse. Biol Blood Marrow Transplant 18:1800\u20131807. https:\/\/doi.org\/10.1016\/j.bbmt.2012.05.010","journal-title":"Biol Blood Marrow Transplant"},{"key":"5288_CR30","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41409-018-0093-9","volume":"53","author":"N Alhashim","year":"2018","unstructured":"Alhashim N, Aljurf M, Hassanein M et al (2018) Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia: clinical characteristics, incidence, risk factors and outcomes. Bone Marrow Transplant 53:838\u2013843. https:\/\/doi.org\/10.1038\/s41409-018-0093-9","journal-title":"Bone Marrow Transplant"},{"key":"5288_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41409-020-0984-4","volume":"56","author":"JJ Frietsch","year":"2021","unstructured":"Frietsch JJ, Hunstig F, Wittke C et al (2021) Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity. Bone Marrow Transplant 56:101\u2013109. https:\/\/doi.org\/10.1038\/s41409-020-0984-4","journal-title":"Bone Marrow Transplant"},{"key":"5288_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3324\/haematol.2012.073189","volume":"98","author":"AC Harris","year":"2013","unstructured":"Harris AC, Kitko CL, Couriel DR et al (2013) Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Haematologica 98:179\u2013184. https:\/\/doi.org\/10.3324\/haematol.2012.073189","journal-title":"Haematologica"},{"key":"5288_CR33","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1097\/PAS.0000000000000727","volume":"40","author":"K Kawamoto","year":"2016","unstructured":"Kawamoto K, Miyoshi H, Yoshida N et al (2016) Clinicopathological, cytogenetic, and prognostic analysis of 131 myeloid sarcoma patients. Am J Surg Pathol 40:1473\u20131483. https:\/\/doi.org\/10.1097\/PAS.0000000000000727","journal-title":"Am J Surg Pathol"},{"key":"5288_CR34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/ejh.13056","volume":"100","author":"H Claerhout","year":"2018","unstructured":"Claerhout H, Van Aelst S, Melis C et al (2018) Clinicopathological characteristics of de novo and secondary myeloid sarcoma: a monocentric retrospective study. Eur J Haematol 100:603\u2013612. https:\/\/doi.org\/10.1111\/ejh.13056","journal-title":"Eur J Haematol"},{"key":"5288_CR35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/his.13864","volume":"75","author":"DI Ullman","year":"2019","unstructured":"Ullman DI, Dorn D, Jones JA et al (2019) Clinicopathological and molecular characteristics of extramedullary acute myeloid leukaemia. Histopathology 75:185\u2013192. https:\/\/doi.org\/10.1111\/his.13864","journal-title":"Histopathology"},{"key":"5288_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3390\/cancers11030311","volume":"11","author":"R Windisch","year":"2019","unstructured":"Windisch R, Pirschtat N, Kellner C et al (2019) Oncogenic deregulation of cell adhesion molecules in leukemia. Cancers (Basel) 11:311. https:\/\/doi.org\/10.3390\/cancers11030311","journal-title":"Cancers (Basel)"},{"key":"5288_CR37","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1002\/1097-0142(19940415)73:8<2107::AID-CNCR2820730815>3.0.CO;2-W","volume":"73","author":"JC Byrd","year":"1994","unstructured":"Byrd JC, Weiss RB (1994) Recurrent granulocytic sarcoma. An unusual variation of acute myelogenous leukemia associated with 8;21 chromosomal translocation and blast expression of the neural cell adhesion molecule. Cancer 73:2107\u20132112. https:\/\/doi.org\/10.1002\/1097-0142(19940415)73:8<2107::AID-CNCR2820730815>3.0.CO;2-W","journal-title":"Cancer"},{"key":"5288_CR38","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1182\/blood.V80.12.3182.3182","volume":"80","author":"CA Hurwitz","year":"1992","unstructured":"Hurwitz CA, Raimondi SC, Head D et al (1992) Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 80:3182\u20133188","journal-title":"Blood"},{"key":"5288_CR39","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1182\/blood.V90.4.1643","volume":"90","author":"MR Baer","year":"1997","unstructured":"Baer MR, Stewart CC, Lawrence D et al (1997) Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 90:1643\u20131648","journal-title":"Blood"},{"key":"5288_CR40","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1126\/science.3576199","volume":"236","author":"BA Cunningham","year":"1987","unstructured":"Cunningham BA, Hemperly JJ, Murray BA et al (1987) Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science 236:799\u2013806. https:\/\/doi.org\/10.1126\/science.3576199","journal-title":"Science"},{"key":"5288_CR41","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.leukres.2004.01.006","volume":"28","author":"H Chang","year":"2004","unstructured":"Chang H, Brandwein J, Chun K, Patterson B, Brien B (2004) Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leuk Res 28:1007\u20131011. https:\/\/doi.org\/10.1016\/j.leukres.2004.01.006","journal-title":"Leuk Res"},{"key":"5288_CR42","first-page":"869","volume":"9","author":"MAKGWHMC Reuss-Borst","year":"1995","unstructured":"Reuss-Borst MAKGWHMC (1995) Differential expression of adhesion molecules in acute leukemia. Leukemia 9:869\u2013874","journal-title":"Leukemia"},{"key":"5288_CR43","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00277-014-2082-4","volume":"93","author":"J Junc\u00e0","year":"2014","unstructured":"Junc\u00e0 J, Garcia-Caro M, Granada I et al (2014) Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosis. Ann Hematol 93:1483\u20131489. https:\/\/doi.org\/10.1007\/s00277-014-2082-4","journal-title":"Ann Hematol"},{"key":"5288_CR44","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/pbc.22500","volume":"55","author":"CMJM Faaij","year":"2010","unstructured":"Faaij CMJM, Willemze AJ, R\u00e9v\u00e9sz T et al (2010) Chemokine\/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: differential roles for CCR2, CCR5, CXCR4 and CXCR7. Pediatr Blood Cancer 55:344\u2013348. https:\/\/doi.org\/10.1002\/pbc.22500","journal-title":"Pediatr Blood Cancer"},{"key":"5288_CR45","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1365-2141.2007.06590.x","volume":"137","author":"JA Burger","year":"2007","unstructured":"Burger JA, B\u00fcrkle A (2007) The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol 137:288\u2013296. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06590.x","journal-title":"Br J Haematol"},{"key":"5288_CR46","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood.2022017046","volume":"141","author":"L-X Yang","year":"2023","unstructured":"Yang L-X, Zhang C-T, Yang M-Y et al (2023) C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse. Blood 141:766\u2013786. https:\/\/doi.org\/10.1182\/blood.2022017046","journal-title":"Blood"},{"key":"5288_CR47","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/hon.2506","volume":"36","author":"K Kawamoto","year":"2018","unstructured":"Kawamoto K, Miyoshi H, Suzuki T et al (2018) Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients. Hematol Oncol 36:591\u2013599. https:\/\/doi.org\/10.1002\/hon.2506","journal-title":"Hematol Oncol"},{"key":"5288_CR48","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1080\/10428194.2019.1675880","volume":"62","author":"KS Meleveedu","year":"2021","unstructured":"Meleveedu KS, Chen D, Nadiminti K et al (2021) PD-1\/PD-L1 expression in extramedullary lesions of acute myeloid leukemia. Leuk Lymphoma 62:764\u2013767. https:\/\/doi.org\/10.1080\/10428194.2019.1675880","journal-title":"Leuk Lymphoma"},{"key":"5288_CR49","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/ajh.25109","volume":"93","author":"GG Loscocco","year":"2018","unstructured":"Loscocco GG, Piccini M, Vergoni F et al (2018) A case of disseminated blastic plasmocytoid dendritic cell neoplasm. Am J Hematol 93:1433\u20131434. https:\/\/doi.org\/10.1002\/ajh.25109","journal-title":"Am J Hematol"},{"key":"5288_CR50","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/1097-0142(19810915)48:6<1426::AID-CNCR2820480626>3.0.CO;2-G","volume":"48","author":"RS Neiman","year":"1981","unstructured":"Neiman RS, Barcos M, Berard C et al (1981) Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer 48:1426\u20131437. https:\/\/doi.org\/10.1002\/1097-0142(19810915)48:6<1426::AID-CNCR2820480626>3.0.CO;2-G","journal-title":"Cancer"},{"key":"5288_CR51","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/modpathol.3800768","volume":"20","author":"DP O\u2019Malley","year":"2007","unstructured":"O\u2019Malley DP (2007) Benign extramedullary myeloid proliferations. Mod Pathol 20:405\u2013415. https:\/\/doi.org\/10.1038\/modpathol.3800768","journal-title":"Mod Pathol"},{"key":"5288_CR52","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1309\/AJCPO58YWIBUBESX","volume":"144","author":"CS Wilson","year":"2015","unstructured":"Wilson CS, Medeiros LJ (2015) Extramedullary manifestations of myeloid neoplasms. Am J Clin Pathol 144:219\u2013239. https:\/\/doi.org\/10.1309\/AJCPO58YWIBUBESX","journal-title":"Am J Clin Pathol"},{"key":"5288_CR53","doi-asserted-by":"publisher","unstructured":"Yamauchi K, Yasuda M (2002) Comparison in treatments of nonleukemic granulocytic sarcoma. Cancer 94. https:\/\/doi.org\/10.1002\/cncr.10399","DOI":"10.1002\/cncr.10399"},{"issue":"4","key":"5288_CR54","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.anndiagpath.2014.06.001","volume":"18","author":"RP Seifert","year":"2014","unstructured":"Seifert RP, Bulkeley W, Zhang L et al (2014) A practical approach to diagnose soft tissue myeloid sarcoma preceding or coinciding with acute myeloid leukemia. Ann Diagn Pathol 18(4):253\u2013260. https:\/\/doi.org\/10.1016\/j.anndiagpath.2014.06.001","journal-title":"Ann Diagn Pathol"},{"key":"5288_CR55","first-page":"790","volume":"119","author":"MJ Roth","year":"1995","unstructured":"Roth MJ, Medeiros LJ, Elenitoba-Johnson K et al (1995) Extramedullary myeloid cell tumors. An immunohistochemical study of 29 cases using routinely fixed and processed paraffin-embedded tissue sections. Arch Pathol Lab Med 119:790\u2013798","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"5288_CR56","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1309\/AJCP1ZA7HYZKAZHS","volume":"132","author":"C Campidelli","year":"2009","unstructured":"Campidelli C, Agostinelli C, Stitson R, Pileri SA (2009) Myeloid sarcoma. Am J Clin Pathol 132(3):426\u2013437. https:\/\/doi.org\/10.1309\/AJCP1ZA7HYZKAZHS","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"5288_CR57","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1309\/AJCPO58YWIBUBESX","volume":"144","author":"CS Wilson","year":"2015","unstructured":"Wilson CS, Medeiros LJ (2015) Extramedullary manifestations of myeloid neoplasms. Am J Clin Pathol 144(2):219\u2013239. https:\/\/doi.org\/10.1309\/AJCPO58YWIBUBESX","journal-title":"Am J Clin Pathol"},{"key":"5288_CR58","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.2214\/ajr.176.6.1761427","volume":"176","author":"GC Ooi","year":"2001","unstructured":"Ooi GC, Chim CS, Khong PL et al (2001) Radiologic manifestations of granulocytic sarcoma in adult leukemia. Am J Roentgenol 176:1427\u20131431. https:\/\/doi.org\/10.2214\/ajr.176.6.1761427","journal-title":"Am J Roentgenol"},{"key":"5288_CR59","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1148\/radiol.2433060747","volume":"243","author":"EK Choi","year":"2007","unstructured":"Choi EK, Ha HK, Park SH et al (2007) Granulocytic sarcoma of bowel: CT findings. Radiology 243:752\u2013759. https:\/\/doi.org\/10.1148\/radiol.2433060747","journal-title":"Radiology"},{"key":"5288_CR60","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3342\/ceo.2009.2.2.66","volume":"2","author":"BW Noh","year":"2009","unstructured":"Noh BW, Park S-W, Chun J-E et al (2009) Granulocytic sarcoma in the head and neck: CT and MR imaging findings. Clin Exp Otorhinolaryngol 2:66. https:\/\/doi.org\/10.3342\/ceo.2009.2.2.66","journal-title":"Clin Exp Otorhinolaryngol"},{"key":"5288_CR61","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/RCT.0000000000000337","volume":"40","author":"AA Chaudhry","year":"2016","unstructured":"Chaudhry AA, Gul M, Chaudhry AA, Dunkin J (2016) Qualitative assessment of diffusion weighted imaging and susceptibility weighted imaging of myeloid sarcoma involving the brain. J Comput Assist Tomogr 40:61\u201366. https:\/\/doi.org\/10.1097\/RCT.0000000000000337","journal-title":"J Comput Assist Tomogr"},{"key":"5288_CR62","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3324\/haematol.2011.045047","volume":"96","author":"F Stolzel","year":"2011","unstructured":"Stolzel F, Rollig C, Radke J et al (2011) 18F-FDG-PET\/CT for detection of extramedullary acute myeloid leukemia. Haematologica 96:1552\u20131556. https:\/\/doi.org\/10.3324\/haematol.2011.045047","journal-title":"Haematologica"},{"key":"5288_CR63","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/ejh.12085","volume":"90","author":"A-SWI Cribe","year":"2013","unstructured":"Cribe A-SWI, Steenhof M, Marcher CW et al (2013) Extramedullary disease in patients with acute myeloid leukemia assessed by (18)F-FDG PET. Eur J Haematol 90:273\u2013278. https:\/\/doi.org\/10.1111\/ejh.12085","journal-title":"Eur J Haematol"},{"key":"5288_CR64","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/sj.leu.2404699","volume":"21","author":"B Falini","year":"2007","unstructured":"Falini B, Lenze D, Hasserjian R et al (2007) Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia 21:1566\u20131570. https:\/\/doi.org\/10.1038\/sj.leu.2404699","journal-title":"Leukemia"},{"key":"5288_CR65","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1309\/WWW7-DG6X-HC16-D7J2","volume":"114","author":"C-C Chang","year":"2000","unstructured":"Chang C-C, Eshoa C, Kampalath B et al (2000) Immunophenotypic profile of myeloid cells in granulocytic sarcoma by immunohistochemistry. Am J Clin Pathol 114:807\u2013811. https:\/\/doi.org\/10.1309\/WWW7-DG6X-HC16-D7J2","journal-title":"Am J Clin Pathol"},{"key":"5288_CR66","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/modpathol.2013.238","volume":"27","author":"NA Sangle","year":"2014","unstructured":"Sangle NA, Schmidt RL, Patel JL et al (2014) Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm. Mod Pathol 27:1137\u20131143. https:\/\/doi.org\/10.1038\/modpathol.2013.238","journal-title":"Mod Pathol"},{"issue":"1","key":"5288_CR67","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/10245332.2017.1333275","volume":"23","author":"V Kaur","year":"2018","unstructured":"Kaur V, Swami A, Alapat D et al (2018) Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years. Hematology 23(1):17\u201324. https:\/\/doi.org\/10.1080\/10245332.2017.1333275","journal-title":"Hematology"},{"key":"5288_CR68","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/labmed\/lmab025","volume":"53","author":"VJ Dayton","year":"2022","unstructured":"Dayton VJ, Beckman A, Linden M (2022) Myeloid sarcoma expressing keratins and mimicking carcinoma\u2014case report and literature review. Lab Med 53:100\u2013106. https:\/\/doi.org\/10.1093\/labmed\/lmab025","journal-title":"Lab Med"},{"key":"5288_CR69","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.prp.2016.06.014","volume":"212","author":"H-Q Wang","year":"2016","unstructured":"Wang H-Q, Li J (2016) Clinicopathological features of myeloid sarcoma: report of 39 cases and literature review. Pathol-Res Pract 212:817\u2013824. https:\/\/doi.org\/10.1016\/j.prp.2016.06.014","journal-title":"Pathol-Res Pract"},{"key":"5288_CR70","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1200\/JOP.18.00753","volume":"15","author":"AS Kanate","year":"2019","unstructured":"Kanate AS, Vos J, Chargualaf MJ (2019) Venetoclax for refractory myeloid sarcoma. J Oncol Pract 15:413\u2013415. https:\/\/doi.org\/10.1200\/JOP.18.00753","journal-title":"J Oncol Pract"},{"key":"5288_CR71","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/ajcp\/aqaa216","volume":"156","author":"RL King","year":"2021","unstructured":"King RL, Siaghani PJ, Wong K et al (2021) Novel t(1;8)(p31.3;q21.3) NFIA-RUNX1T1 translocation in an infant erythroblastic sarcoma. Am J Clin Pathol 156:129\u2013138. https:\/\/doi.org\/10.1093\/ajcp\/aqaa216","journal-title":"Am J Clin Pathol"},{"key":"5288_CR72","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/ajcp\/aqw033","volume":"145","author":"H Li","year":"2016","unstructured":"Li H, Hasserjian RP, Kroft SH et al (2016) Pure erythroid leukemia and erythroblastic sarcoma evolving from chronic myeloid neoplasms. Am J Clin Pathol 145:538\u2013551. https:\/\/doi.org\/10.1093\/ajcp\/aqw033","journal-title":"Am J Clin Pathol"},{"key":"5288_CR73","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1080\/10428190600881231","volume":"47","author":"G Famoso","year":"2006","unstructured":"Famoso G, Ponzoni M, Freschi M et al (2006) Megakaryoblastic differentiation of myeloid sarcoma in a patient with essential thrombocythemia. Leuk Lymphoma 47:2414\u20132417. https:\/\/doi.org\/10.1080\/10428190600881231","journal-title":"Leuk Lymphoma"},{"key":"5288_CR74","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000488057","volume":"5","author":"FA Jakobiec","year":"2019","unstructured":"Jakobiec FA, Wolkow N, Zakka FR, Rubin PAD (2019) Myeloid sarcoma with megakaryoblastic differentiation arising in the conjunctiva. Ocul Oncol Pathol 5:28\u201335. https:\/\/doi.org\/10.1159\/000488057","journal-title":"Ocul Oncol Pathol"},{"key":"5288_CR75","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.leukres.2004.03.021","volume":"28","author":"MS Tallman","year":"2004","unstructured":"Tallman MS (2004) Extramedullay acute myeloid leukemia infiltrates. Leuk Res 28:1005\u20131006. https:\/\/doi.org\/10.1016\/j.leukres.2004.03.021","journal-title":"Leuk Res"},{"key":"5288_CR76","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1200\/JCO.1995.13.7.1800","volume":"13","author":"JC Byrd","year":"1995","unstructured":"Byrd JC, Edenfield WJ, Shields DJ, Dawson NA (1995) Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol 13:1800\u20131816. https:\/\/doi.org\/10.1200\/JCO.1995.13.7.1800","journal-title":"J Clin Oncol"},{"key":"5288_CR77","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/BF01696563","volume":"69","author":"K Krishnan","year":"1994","unstructured":"Krishnan K, Ross CW, Adams PT et al (1994) Neural cell-adhesion molecule (CD 56)-positive, t(8; 21) acute myeloid leukemia (AML, M-2) and granulocytic sarcoma. Ann Hematol 69:321\u2013323. https:\/\/doi.org\/10.1007\/BF01696563","journal-title":"Ann Hematol"},{"key":"5288_CR78","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1200\/JCO.1993.11.4.690","volume":"11","author":"MS Tallman","year":"1993","unstructured":"Tallman MS, Hakimian D, Shaw JM et al (1993) Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin Oncol 11:690\u2013697. https:\/\/doi.org\/10.1200\/JCO.1993.11.4.690","journal-title":"J Clin Oncol"},{"key":"5288_CR79","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1755-7682-4-3","volume":"4","author":"P Alvarez","year":"2011","unstructured":"Alvarez P, Navascues CA, Ordieres C et al (2011) Granulocytic sarcoma of the small bowel, greater omentum and peritoneum associated with a CBFbeta\/MYH11 fusion and inv(16) (p13q22): a case report. Int Arch Med 4:3. https:\/\/doi.org\/10.1186\/1755-7682-4-3","journal-title":"Int Arch Med"},{"key":"5288_CR80","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.leukres.2010.01.009","volume":"34","author":"X-H Zhang","year":"2010","unstructured":"Zhang X-H, Zhang R, Li Y (2010) Granulocytic sarcoma of abdomen in acute myeloid leukemia patient with inv(16) and t(6;17) abnormal chromosome: Case report and review of literature. Leuk Res 34:958\u2013961. https:\/\/doi.org\/10.1016\/j.leukres.2010.01.009","journal-title":"Leuk Res"},{"key":"5288_CR81","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/j.clml.2014.06.027","volume":"14","author":"M Ohanian","year":"2014","unstructured":"Ohanian M, Huang RSP, Yakoushina TV et al (2014) Isolated mesenteric CD20-positive myeloid sarcoma. Clin Lymphoma Myeloma Leuk 14:e217\u2013e220. https:\/\/doi.org\/10.1016\/j.clml.2014.06.027","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5288_CR82","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/ajh.23821","volume":"89","author":"M Solh","year":"2014","unstructured":"Solh M, Yohe S, Weisdorf D, Ustun C (2014) Core-binding factor acute myeloid leukemia: heterogeneity, monitoring, and therapy. Am J Hematol 89:1121\u20131131. https:\/\/doi.org\/10.1002\/ajh.23821","journal-title":"Am J Hematol"},{"key":"5288_CR83","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/ajcp\/75.2.140","volume":"75","author":"L Peterson","year":"1981","unstructured":"Peterson L, Dehner LP, Brunning RD (1981) Extramedullary masses as presenting features of acute monoblastic leukemia. Am J Clin Pathol 75:140\u2013148. https:\/\/doi.org\/10.1093\/ajcp\/75.2.140","journal-title":"Am J Clin Pathol"},{"key":"5288_CR84","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3109\/10428199409049646","volume":"14","author":"SA Ridge","year":"1994","unstructured":"Ridge SA, Wiedemann LM (1994) Chromosome 11q23 abnormalities in leukaemia. Leuk Lymphoma 14:11\u201317. https:\/\/doi.org\/10.3109\/10428199409049646","journal-title":"Leuk Lymphoma"},{"key":"5288_CR85","doi-asserted-by":"publisher","unstructured":"Ali Ansari-Lari M, Yang C-F, Tinawi-Aljundi R et al (2004) FLT3 mutations in myeloid sarcoma. Br J Haematol 126. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05124.x","DOI":"10.1111\/j.1365-2141.2004.05124.x"},{"key":"5288_CR86","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/10428194.2017.1339879","volume":"59","author":"K Kashofer","year":"2018","unstructured":"Kashofer K, Gornicec M, Lind K et al (2018) Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing. Leuk Lymphoma 59:501\u2013504. https:\/\/doi.org\/10.1080\/10428194.2017.1339879","journal-title":"Leuk Lymphoma"},{"key":"5288_CR87","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1002\/cncr.34459","volume":"128","author":"S Ball","year":"2022","unstructured":"Ball S, Knepper TC, Deutsch YE et al (2022) Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations. Cancer 128:3880\u20133887. https:\/\/doi.org\/10.1002\/cncr.34459","journal-title":"Cancer"},{"issue":"4","key":"5288_CR88","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1080\/10428194.2016.1225208","volume":"58","author":"C Pastoret","year":"2017","unstructured":"Pastoret C, Houot R, Llamas-Gutierrez F et al (2017) Detection of clonal heterogeneity and targetable mutations in myeloid sarcoma by high-throughput sequencing. Leuk Lymphoma 58(4):1008\u20131012. https:\/\/doi.org\/10.1080\/10428194.2016.1225208","journal-title":"Leuk Lymphoma"},{"key":"5288_CR89","doi-asserted-by":"publisher","unstructured":"Ramia de Cap M, Wu LP, Hirt C et al (2023) Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group. Leuk Lymphoma:1\u20139. https:\/\/doi.org\/10.1080\/10428194.2023.2185091","DOI":"10.1080\/10428194.2023.2185091"},{"key":"5288_CR90","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41408-018-0083-6","volume":"8","author":"M Choi","year":"2018","unstructured":"Choi M, Jeon YK, Sun C-H et al (2018) RTK-RAS pathway mutation is enriched in myeloid sarcoma. Blood Cancer J 8:43. https:\/\/doi.org\/10.1038\/s41408-018-0083-6","journal-title":"Blood Cancer J"},{"key":"5288_CR91","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13045-022-01267-7","volume":"15","author":"J-N Eckardt","year":"2022","unstructured":"Eckardt J-N, St\u00f6lzel F, Kunadt D et al (2022) Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. J Hematol Oncol 15:60. https:\/\/doi.org\/10.1186\/s13045-022-01267-7","journal-title":"J Hematol Oncol"},{"issue":"9","key":"5288_CR92","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1038\/s41375-018-0056-6","volume":"32","author":"C Willekens","year":"2018","unstructured":"Willekens C, Renneville A, Broutin S et al (2018) Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1\/2 mutations. Leukemia 32(9):2008\u20132081. https:\/\/doi.org\/10.1038\/s41375-018-0056-6","journal-title":"Leukemia"},{"key":"5288_CR93","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.humpath.2020.11.005","volume":"108","author":"NY Greenland","year":"2021","unstructured":"Greenland NY, Van Ziffle JA, Liu Y-C et al (2021) Genomic analysis in myeloid sarcoma and comparison with paired acute myeloid leukemia. Hum Pathol 108:76\u201383. https:\/\/doi.org\/10.1016\/j.humpath.2020.11.005","journal-title":"Hum Pathol"},{"key":"5288_CR94","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1080\/10428190600967196","volume":"47","author":"S Paydas","year":"2006","unstructured":"Paydas S, Zorludemir S, Ergin M (2006) Granulocytic sarcoma: 32 cases and review of the literature. Leuk Lymphoma 47:2527\u20132541. https:\/\/doi.org\/10.1080\/10428190600967196","journal-title":"Leuk Lymphoma"},{"key":"5288_CR95","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1200\/JCO.1997.15.2.466","volume":"15","author":"JC Byrd","year":"1997","unstructured":"Byrd JC, Weiss RB, Arthur DC et al (1997) Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol 15:466\u2013475. https:\/\/doi.org\/10.1200\/JCO.1997.15.2.466","journal-title":"J Clin Oncol"},{"key":"5288_CR96","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/bjh.17742","volume":"195","author":"KH Begna","year":"2021","unstructured":"Begna KH, Kittur J, Yui J et al (2021) De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. Br J Haematol 195:413\u2013416. https:\/\/doi.org\/10.1111\/bjh.17742","journal-title":"Br J Haematol"},{"key":"5288_CR97","doi-asserted-by":"publisher","unstructured":"Dusenbery KE, Howells WB, Arthur DC, et al (2003) Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia. J Pediatr Hematol Oncol 25:760\u2013768. https:\/\/doi.org\/10.1097\/00043426-200310000-00004","DOI":"10.1097\/00043426-200310000-00004"},{"key":"5288_CR98","doi-asserted-by":"publisher","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","volume":"17","author":"MS Tallman","year":"2019","unstructured":"Tallman MS, Wang ES, Altman JK et al (2019) Acute myeloid leukemia, version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 17:721\u2013749. https:\/\/doi.org\/10.6004\/jnccn.2019.0028","journal-title":"J Natl Compr Cancer Netw"},{"key":"5288_CR99","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/0360-3016(83)90176-1","volume":"9","author":"LY Chak","year":"1983","unstructured":"Chak LY, Sapozink MD, Cox RS (1983) Extramedullary lesions in non-lymphocytic leukemia: results of radiation therapy. Int J Radiat Oncol 9:1173\u20131176. https:\/\/doi.org\/10.1016\/0360-3016(83)90176-1","journal-title":"Int J Radiat Oncol"},{"key":"5288_CR100","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.ijrobp.2011.02.057","volume":"82","author":"R Bakst","year":"2012","unstructured":"Bakst R, Wolden S, Yahalom J (2012) Radiation therapy for chloroma (granulocytic sarcoma). Int J Radiat Oncol 82:1816\u20131822. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.02.057","journal-title":"Int J Radiat Oncol"},{"key":"5288_CR101","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/1748-717X-8-245","volume":"8","author":"W-Y Chen","year":"2013","unstructured":"Chen W-Y, Wang C-W, Chang C-H et al (2013) Clinicopathologic features and responses to radiotherapy of myeloid sarcoma. Radiat Oncol 8:245. https:\/\/doi.org\/10.1186\/1748-717X-8-245","journal-title":"Radiat Oncol"},{"key":"5288_CR102","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1182\/blood.V124.21.960.960","volume":"124","author":"FM Feller","year":"2014","unstructured":"Feller FM, Patel M, Devlin SM et al (2014) The addition of radiation therapy to initial treatment for extramedullary acute myeloid leukemia does not offer a survival benefit when added to chemotherapy. Blood 124:960\u2013960. https:\/\/doi.org\/10.1182\/blood.V124.21.960.960","journal-title":"Blood"},{"key":"5288_CR103","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ijrobp.2018.05.045","volume":"102","author":"RL Bakst","year":"2018","unstructured":"Bakst RL, Dabaja BS, Specht LK, Yahalom J (2018) Use of radiation in extramedullary leukemia\/chloroma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol 102:314\u2013319. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.05.045","journal-title":"Int J Radiat Oncol"},{"key":"5288_CR104","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1182\/blood-2011-04-347229","volume":"118","author":"RL Bakst","year":"2011","unstructured":"Bakst RL, Tallman MS, Douer D, Yahalom J (2011) How I treat extramedullary acute myeloid leukemia. Blood 118:3785\u20133793. https:\/\/doi.org\/10.1182\/blood-2011-04-347229","journal-title":"Blood"},{"key":"5288_CR105","doi-asserted-by":"publisher","first-page":"351","DOI":"10.7326\/0003-4819-123-5-199509010-00005","volume":"123","author":"KR Imrie","year":"1995","unstructured":"Imrie KR (1995) Isolated chloroma: the effect of early antileukemic therapy. Ann Intern Med 123:351. https:\/\/doi.org\/10.7326\/0003-4819-123-5-199509010-00005","journal-title":"Ann Intern Med"},{"key":"5288_CR106","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"5288_CR107","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3109\/10428194.2012.702905","volume":"54","author":"A Serrao","year":"2013","unstructured":"Serrao A, Loglisci G, Salaroli A et al (2013) Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization. Leuk Lymphoma 54:411\u2013412. https:\/\/doi.org\/10.3109\/10428194.2012.702905","journal-title":"Leuk Lymphoma"},{"key":"5288_CR108","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/bmt.2012.256","volume":"48","author":"A Antar","year":"2013","unstructured":"Antar A, Otrock ZK, Kharfan-Dabaja M et al (2013) Azacitidine in the treatment of extramedullary relapse of AML after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 48:994\u2013995. https:\/\/doi.org\/10.1038\/bmt.2012.256","journal-title":"Bone Marrow Transplant"},{"key":"5288_CR109","doi-asserted-by":"publisher","first-page":"e7975","DOI":"10.1097\/MD.0000000000007975","volume":"96","author":"T Katagiri","year":"2017","unstructured":"Katagiri T, Ushiki T, Masuko M et al (2017) Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome. Medicine (Baltimore) 96:e7975. https:\/\/doi.org\/10.1097\/MD.0000000000007975","journal-title":"Medicine (Baltimore)"},{"key":"5288_CR110","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1620\/tjem.254.101","volume":"254","author":"H Okamoto","year":"2021","unstructured":"Okamoto H, Kamitsuji Y, Komori Y et al (2021) Durable remission of chemotherapy-refractory myeloid sarcoma by azacitidine. Tohoku J Exp Med 254:101\u2013105. https:\/\/doi.org\/10.1620\/tjem.254.101","journal-title":"Tohoku J Exp Med"},{"key":"5288_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/6640597","volume":"2021","author":"K Sato","year":"2021","unstructured":"Sato K, Tsukada N, Inamura J et al (2021) Successful treatment of myeloid sarcoma in an elderly patient with myelodysplastic syndrome with reduced-dose azacitidine. Case Rep Hematol 2021:1\u20138. https:\/\/doi.org\/10.1155\/2021\/6640597","journal-title":"Case Rep Hematol"},{"key":"5288_CR112","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/bmt.2011.210","volume":"47","author":"SN Singh","year":"2012","unstructured":"Singh SN, Cao Q, Gojo I et al (2012) Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT. Bone Marrow Transplant 47:1008\u20131009. https:\/\/doi.org\/10.1038\/bmt.2011.210","journal-title":"Bone Marrow Transplant"},{"key":"5288_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/957490","volume":"2015","author":"G Modi","year":"2015","unstructured":"Modi G, Madabhavi I, Panchal H et al (2015) Primary vaginal myeloid sarcoma: a rare case report and review of the literature. Case Rep Obstet Gynecol 2015:1\u20134. https:\/\/doi.org\/10.1155\/2015\/957490","journal-title":"Case Rep Obstet Gynecol"},{"key":"5288_CR114","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00277-016-2870-0","volume":"96","author":"M Gornicec","year":"2017","unstructured":"Gornicec M, W\u00f6lfler A, Stanzel S et al (2017) Evidence for a role of decitabine in the treatment of myeloid sarcoma. Ann Hematol 96:505\u2013506. https:\/\/doi.org\/10.1007\/s00277-016-2870-0","journal-title":"Ann Hematol"},{"key":"5288_CR115","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00277-018-3314-9","volume":"97","author":"A Castelli","year":"2018","unstructured":"Castelli A, Mosca-Siez ML, Riccomagno P et al (2018) Efficacy and safety of decitabine against cutaneous granuloblastic sarcoma: a case report. Ann Hematol 97:1485\u20131486. https:\/\/doi.org\/10.1007\/s00277-018-3314-9","journal-title":"Ann Hematol"},{"key":"5288_CR116","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12185-018-2470-y","volume":"108","author":"D Evers","year":"2018","unstructured":"Evers D, B\u00e4r BMAM, Gotthardt M, van der Velden WJFM (2018) Activity of decitabine in pericardial myeloid sarcoma. Int J Hematol 108:121\u2013122. https:\/\/doi.org\/10.1007\/s12185-018-2470-y","journal-title":"Int J Hematol"},{"key":"5288_CR117","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3324\/haematol.2022.280798","volume":"108","author":"R Mohty","year":"2023","unstructured":"Mohty R, El Hamed R, Brissot E et al (2023) New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia. Haematologica 108:321\u2013341. https:\/\/doi.org\/10.3324\/haematol.2022.280798","journal-title":"Haematologica"},{"key":"5288_CR118","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1002\/cncr.34182","volume":"128","author":"X Chen","year":"2022","unstructured":"Chen X, Huang J, Xu N et al (2022) A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia. Cancer 128:2138\u20132147. https:\/\/doi.org\/10.1002\/cncr.34182","journal-title":"Cancer"},{"key":"5288_CR119","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12185-020-02855-4","volume":"112","author":"M Kida","year":"2020","unstructured":"Kida M, Kuroda Y, Kido M et al (2020) Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation. Int J Hematol 112:243\u2013248. https:\/\/doi.org\/10.1007\/s12185-020-02855-4","journal-title":"Int J Hematol"},{"key":"5288_CR120","doi-asserted-by":"publisher","first-page":"100219","DOI":"10.1016\/j.lrr.2020.100219","volume":"14","author":"T Kumode","year":"2020","unstructured":"Kumode T, Rai S, Tanaka H et al (2020) Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. Leuk Res Reports 14:100219. https:\/\/doi.org\/10.1016\/j.lrr.2020.100219","journal-title":"Leuk Res Reports"},{"key":"5288_CR121","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000518356","volume":"66","author":"S Perrone","year":"2021","unstructured":"Perrone S, Ortu La Barbera E, Viola F et al (2021) A relapsing meningeal acute myeloid leukaemia FLT3-ITD+ responding to gilteritinib. Chemotherapy 66:134\u2013138. https:\/\/doi.org\/10.1159\/000518356","journal-title":"Chemotherapy"},{"key":"5288_CR122","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1001\/jamaophthalmol.2020.0110","volume":"138","author":"RS Kim","year":"2020","unstructured":"Kim RS, Yaghy A, Wilde LR, Shields CL (2020) An iridociliochoroidal myeloid sarcoma associated with relapsed acute myeloid leukemia with FLT3-ITD mutation, Treated With Gilteritinib, an FLT3 Inhibitor. JAMA Ophthalmol 138:418. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.0110","journal-title":"JAMA Ophthalmol"},{"key":"5288_CR123","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00277-021-04702-w","volume":"101","author":"RM Shallis","year":"2022","unstructured":"Shallis RM, Pucar D, Perincheri S et al (2022) Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy. Ann Hematol 101:1145\u20131147. https:\/\/doi.org\/10.1007\/s00277-021-04702-w","journal-title":"Ann Hematol"},{"key":"5288_CR124","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1159\/000524878","volume":"145","author":"G Arrigo","year":"2022","unstructured":"Arrigo G, D\u2019Ard\u00eca S, Audisio E et al (2022) Gilteritinib in isolated breast relapse of FLT3 positive acute myeloid leukemia: a case report and review of literature. Acta Haematol 145:566\u2013570. https:\/\/doi.org\/10.1159\/000524878","journal-title":"Acta Haematol"},{"key":"5288_CR125","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12905-021-01328-y","volume":"21","author":"A Shatilova","year":"2021","unstructured":"Shatilova A, Girshova L, Zaytsev D et al (2021) The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report. BMC Womens Health 21:184. https:\/\/doi.org\/10.1186\/s12905-021-01328-y","journal-title":"BMC Womens Health"},{"key":"5288_CR126","doi-asserted-by":"publisher","first-page":"100286","DOI":"10.1016\/j.lrr.2021.100286","volume":"17","author":"N Mandhan","year":"2022","unstructured":"Mandhan N, Yassine F, Li K, Badar T (2022) Bladder myeloid sarcoma with TP53 mutated myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndrome: response to decitabine-venetoclax regimen. Leuk Res Reports 17:100286. https:\/\/doi.org\/10.1016\/j.lrr.2021.100286","journal-title":"Leuk Res Reports"},{"key":"5288_CR127","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/10781552221110826","volume":"29","author":"F De la Garza-Salazar","year":"2023","unstructured":"De la Garza-Salazar F, Pe\u00f1a-Lozano SP, G\u00f3mez-Almaguer D, Colunga-Pedraza PR (2023) Orbital myeloid sarcoma treated with low-dose venetoclax and a potent cytochrome P450 inhibitor. J Oncol Pharm Pract 29:493\u2013497. https:\/\/doi.org\/10.1177\/10781552221110826","journal-title":"J Oncol Pharm Pract"},{"key":"5288_CR128","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00280-021-04356-5","volume":"89","author":"A Condorelli","year":"2022","unstructured":"Condorelli A, Matteo C, Leotta S et al (2022) Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement. Cancer Chemother Pharmacol 89:267\u2013270. https:\/\/doi.org\/10.1007\/s00280-021-04356-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"5288_CR129","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","volume":"108","author":"C Schmid","year":"2006","unstructured":"Schmid C (2006) Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108:1092\u20131099. https:\/\/doi.org\/10.1182\/blood-2005-10-4165","journal-title":"Blood"},{"key":"5288_CR130","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3324\/haematol.2009.013920","volume":"95","author":"C Craddock","year":"2010","unstructured":"Craddock C, Nagra S, Peniket A et al (2010) Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 95:989\u2013995. https:\/\/doi.org\/10.3324\/haematol.2009.013920","journal-title":"Haematologica"},{"key":"5288_CR131","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3109\/10428194.2012.720375","volume":"54","author":"N Kogut","year":"2013","unstructured":"Kogut N, Tsai N-C, Thomas SH et al (2013) Extramedullary relapse following reduced intensity allogeneic hematopoietic cell transplant for adult acute myelogenous leukemia. Leuk Lymphoma 54:665\u2013668. https:\/\/doi.org\/10.3109\/10428194.2012.720375","journal-title":"Leuk Lymphoma"},{"key":"5288_CR132","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.1200\/JCO.2007.15.6315","volume":"26","author":"P Chevallier","year":"2008","unstructured":"Chevallier P, Mohty M, Lioure B et al (2008) Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC. J Clin Oncol 26:4940\u20134943. https:\/\/doi.org\/10.1200\/JCO.2007.15.6315","journal-title":"J Clin Oncol"},{"key":"5288_CR133","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1038\/leu.2012.156","volume":"26","author":"H Shimizu","year":"2012","unstructured":"Shimizu H, Saitoh T, Tanaka M et al (2012) Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma. Leukemia 26:2469\u20132473. https:\/\/doi.org\/10.1038\/leu.2012.156","journal-title":"Leukemia"},{"key":"5288_CR134","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/bmt.2015.82","volume":"50","author":"SD Goyal","year":"2015","unstructured":"Goyal SD, Zhang M-J, Wang H-L et al (2015) Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. Bone Marrow Transplant 50:1057\u20131062. https:\/\/doi.org\/10.1038\/bmt.2015.82","journal-title":"Bone Marrow Transplant"},{"key":"5288_CR135","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41409-022-01882-5","volume":"58","author":"R Swoboda","year":"2023","unstructured":"Swoboda R, Labopin M, Giebel S et al (2023) Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant 58:282\u2013287. https:\/\/doi.org\/10.1038\/s41409-022-01882-5","journal-title":"Bone Marrow Transplant"},{"key":"5288_CR136","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3324\/haematol.2020.249458","volume":"106","author":"CE Dandoy","year":"2020","unstructured":"Dandoy CE, Davies SM, Ahn KW et al (2020) Comparison of total body irradiation versus non-total body irradiation containing regimens for de novo acute myeloid leukemia in children. Haematologica 106:1839\u20131845. https:\/\/doi.org\/10.3324\/haematol.2020.249458","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05288-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05288-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05288-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T07:06:43Z","timestamp":1689232003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05288-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":136,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["5288"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05288-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"assertion":[{"value":"20 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The funders had no role in the design of the study; in the collection, analyses, and interpretation of data; and in the writing of the present manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"G. G. L. has received fees from Novartis; A. M. V. has received speaker fees from Novartis, AOP Health, Incyte, AbbVie, GlaxoSmithKline (GSK), and Bristol Myers Squibb (BMS); and has participated to the advisory boards of Novartis, Incyte, AOP Orphan Pharmaceuticals, AbbVie, GSK, BMS, and Roche.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}